Robin L. Washington net worth and biography

Robin Washington Biography and Net Worth

CFO of Gilead Sciences

Ms. Washington served as Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc. (Gilead), a research-based biopharmaceutical company, from May 2008 through October 2019. In that role, she oversaw Gilead’s Global Finance, Investor Relations, and Information Technology organizations. From 2006 through 2007, Ms. Washington served as Chief Financial Officer of Hyperion Solutions, an enterprise software company that was acquired by Oracle Corporation in March 2007. Prior to that, Ms. Washington spent nearly 10 years at PeopleSoft, a provider of enterprise application software, where she served in a number of executive positions, including Senior Vice President and Corporate Controller. Ms. Washington is a Certified Public Accountant. She is a director of Alphabet Inc., Salesforce.com Inc., and Vertiv Group Corp., and she previously served as a director of Tektronix, Inc. (acquired by Danaher Corporation) (2005-2007) and MIPS Technologies, Inc. (acquired by Imagination Technologies Group PLC) (2008-2013).

What is Robin L. Washington's net worth?: The estimated net worth of Robin L. Washington is at least $4.95 million as of February 28th, 2025. Ms. Washington owns 43,445 shares of Gilead Sciences stock worth more than $4,952,296 as of March 12th. This net worth evaluation does not reflect any other investments that Ms. Washington may own. Learn More about Robin L. Washington's net worth.
How do I contact Robin L. Washington?: The corporate mailing address for Ms. Washington and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at investor_relations@gilead.com. Learn More on Robin L. Washington's contact information.
Has Robin L. Washington been buying or selling shares of Gilead Sciences?: Robin L. Washington has not been actively trading shares of Gilead Sciences during the last ninety days. Most recently, Robin L. Washington sold 5,000 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a transaction totalling $401,550.00. Following the completion of the sale, the chief financial officer now directly owns 23,749 shares of the company's stock, valued at $1,907,282.19. Learn More on Robin L. Washington's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 797,366 shares worth more than $75,721,855.55. The most recent insider tranaction occured on March, 10th when CFO Andrew D Dickinson sold 17,929 shares worth more than $2,118,669.93. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 3/10/2025.

Robin L. Washington Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/28/2018	Sell	5,000	$80.31	$401,550.00	23,749
9/7/2017	Sell	51,820	$85.00	$4,404,700.00	43,352
11/2/2015	Sell	6,250	$109.46	$684,125.00
9/2/2015	Sell	6,250	$102.20	$638,750.00
2/2/2015	Sell	33,192	$105.38	$3,497,772.96
11/3/2014	Sell	33,192	$110.26	$3,659,749.92
8/25/2014	Sell	4,304	$105.87	$455,664.48
8/14/2014	Sell	33,556	$95.56	$3,206,611.36
8/1/2014	Sell	30,600	$91.48	$2,799,288.00
6/30/2014	Sell	10,400	$83.98	$873,392.00
6/4/2014	Sell	6,426	$82.52	$530,273.52
7/1/2013	Sell	45,600	$52.01	$2,371,656.00
11/12/2012	Sell	55,950	$73.11	$4,090,504.50
10/2/2012	Sell	29,500	$68.62	$2,024,290.00

See Full Table

Robin L. Washington Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $113.99

$112.82

$114.87

50 Day Range

MA: $100.56

$89.14

$117.41

2 Week Range

Now: $113.99

$62.07

$119.96

Volume

8,065,860 shs

Average Volume

8,248,752 shs

Market Capitalization

$141.96 billion

P/E Ratio

308.08

Dividend Yield

2.65%

Beta

0.21